Ailanthone restrains hepatocellular carcinoma progression by inducing ferroptosis and disrupting mitochondrial...

Area of Science:

• Oncology
• Biochemistry
• Pharmacology

Background:

• Ailanthone (AIL), a natural compound from Ailanthus species, shows promise in cancer treatment.
• The exact mechanisms of AIL's action in hepatocellular carcinoma (HCC) are not fully understood.

Purpose of the Study:

• To elucidate the molecular mechanisms by which AIL regulates HCC progression.
• To investigate the role of the HSP90/GPX4/ferroptosis axis in AIL's anti-cancer effects.

Main Methods:

• In vitro and in vivo studies on HCC cell proliferation and metastasis.
• Analysis of AIL's interaction with HSP90 and its effect on GPX4 ubiquitination and expression.
• Assessment of ferroptosis induction in HCC cells.
• Evaluation of synergistic effects of AIL combined with GPX4 inhibitors.

Main Results:

• AIL significantly suppressed HCC cell proliferation and metastasis.
• AIL directly interacted with HSP90, promoting GPX4 ubiquitination and reducing GPX4 levels.
• AIL induced ferroptosis in HCC cells.
• Combined AIL and GPX4 inhibitors showed synergistic anti-proliferative effects.

Conclusions:

• The HSP90/GPX4/ferroptosis pathway is crucial for AIL's anti-HCC activity.
• AIL represents a potential therapeutic agent for HCC, acting through the induction of ferroptosis.
• Targeting the HSP90/GPX4 axis offers a promising strategy for HCC treatment.